An observational cohort study examined the effect of statins on diabetes risk and overall mortality in 13,508 normoglycemic patients and 4,563 patients with impaired fasting glucose.
The industry-funded, double-blind, randomized, controlled trial assigned adult patients with type 2 diabetes who were not taking antihyperglycemic agents before the study to 26 weeks of treatment in 1 of 5 arms.
Researchers used data from the ADVANCE-ON study to develop the AD-ON risk score, a 10-year risk score for the combined endpoint of major cardiovascular disease (CVD) or chronic kidney disease.
This month's quiz asks readers to evaluate a 48-year-old woman with type 1 diabetes who experiences occasional episodes of hyperglycemia in the morning before breakfast.
In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years
An industry-funded trial found that those who took empagliflozin had lower rates of mortality, including from cardiovascular (CV) events, than those on placebo. A commentary in ACP Journal Club called the trial results fascinating but said they are not yet sufficient to change practice.
The approval is an expanded indication for the device, which covers the ulcer and allows skin and tissue to regenerate and heal the wound.
The American Association of Clinical Endocrinologists and the American College of Endocrinology updated their algorithm for treatment of type 2 diabetes, while the American Diabetes Association released a position statement on management of diabetes in long-term care and skilled nursing facilities.